Influence of BRAF mutations and RAC1b/RAC1 mRNA ratio or protein expression on outcome in patients with metastatic Colorectal Cancer (mCRC) treated with first-line chemotherapy

被引：0
|
作者：
Cuatrecasas, M. [1 ]
Alonso-Espinaco, V. [1 ]
Jares, P. [1 ]
Horndler, C. [1 ]
Castells, A. [1 ]
Lozano, J. J. [1 ]
Maurel, J. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
来源：
VIRCHOWS ARCHIV | 2012年 / 461卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy
    Alonso-Espinaco, Virginia
    Cuatrecasas, Miriam
    Alonso, Vicente
    Escudero, Pilar
    Marmol, Maribel
    Horndler, Carlos
    Ortego, Javier
    Gallego, Rosa
    Codony-Servat, Jordi
    Garcia-Albeniz, Xabier
    Jares, Pedro
    Castells, Antoni
    Jose Lozano, Juan
    Rosell, Rafael
    Maurel, Joan
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1973 - 1981
  • [2] RAC1b mRNA expression and prognosis in advanced non-small cell lung cancer treated with first-line chemotherapy
    Gasco, A.
    Costa, C.
    Rodriguez, I.
    Bonanno, L.
    Moran, T.
    Karachaliou, N.
    Gimenez-Capitan, A.
    Rodriguez, S.
    Rosell, R.
    Maurel, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S140 - S141
  • [3] Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer
    Cordaro, Aurora
    Barreca, Maria Magdalena
    Zichittella, Chiara
    Loria, Marco
    Anello, Denise
    Arena, Goffredo
    Sciaraffa, Nicolina
    Coronnello, Claudia
    Pizzolanti, Giuseppe
    Alessandro, Riccardo
    Conigliaro, Alice
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [4] The Ratio of RAC1B to RAC1 Expression in Breast Cancer Cell Lines as a Determinant of Epithelial/Mesenchymal Differentiation and Migratory Potential
    Eiden, Caroline
    Ungefroren, Hendrik
    CELLS, 2021, 10 (02) : 1 - 9
  • [5] Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab
    Tejpar, S.
    Bokemeyer, C.
    Celik, I.
    Schlichting, M.
    Sartorius, U.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] KRAS MUTATIONS AND OUTCOME IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CETUXIMAB
    Tejpar, Sabine
    Bokemeyer, Carsten
    Celik, Ilhan
    Schlichting, Michael
    Heeger, Steffen
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v17
  • [7] The RNA-Binding Protein ESRP1 Modulates the Expression of RAC1b in Colorectal Cancer Cells
    Manco, Marta
    Ala, Ugo
    Cantarella, Daniela
    Tolosano, Emanuela
    Medico, Enzo
    Altruda, Fiorella
    Fagoonee, Sharmila
    CANCERS, 2021, 13 (16)
  • [8] Clinical outcomes of patients (Pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated with first-line (1L) chemotherapy regimens
    Parikh, A.
    Tabernero, J.
    Vieira, M. C.
    Kponee-Shovein, K.
    Li, B.
    Cheng, M.
    Liu, J.
    Kang, H.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S44 - S45
  • [9] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
12345